c-MET-mediated resistance to EGFR inhibitors in head and neck
cancer: How to move from bench to bedside

J 2016

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside

SZTURZ, Petr, E. RAYMOND and S. FAIVRE

Basic information

Original name

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), E. RAYMOND (250 France) and S. FAIVRE (250 France)

Edition

Oral oncology, AMSTERDAM, ELSEVIER SCIENCE BV, 2016, 1368-8375

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.794

RIV identification code

RIV/00216224:14110/16:00090826

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.oraloncology.2016.05.017

UT WoS

000380544000005

Keywords in English

squamous-cell carcinoma; randomized phase-ii; tivantinib arq 197; lung-cancer; acquired-resistance; metastatic head; plus erlotinib; double-blind; patients pts; placebo

Abstract

V originále

Mesenchymal–epithelial transition factor (c-MET), found on melanocytes, endothelial cells, and epithelial tissues, is a membrane spanning receptor tyrosine kinase for hepatocyte growth factor (HGF), produced by elements of mesenchymal origin. The receptor-ligand pair controls diverse biological activities including cell proliferation, motility, invasiveness, morphogenesis, apoptosis, and angiogenesis.

Citovat

SZTURZ, Petr, E. RAYMOND and S. FAIVRE. c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside. Oral oncology. AMSTERDAM: ELSEVIER SCIENCE BV, 2016, vol. 59, AUG 2016, p. "E12"-"E14", 3 pp. ISSN 1368-8375. Available from: https://dx.doi.org/10.1016/j.oraloncology.2016.05.017.

@article{1354105,
   author = {Szturz, Petr and Raymond, E. and Faivre, S.},
   article_location = {AMSTERDAM},
   article_number = {AUG 2016},
   doi = {http://dx.doi.org/10.1016/j.oraloncology.2016.05.017},
   keywords = {squamous-cell carcinoma; randomized phase-ii; tivantinib arq 197; lung-cancer; acquired-resistance; metastatic head; plus erlotinib; double-blind; patients pts; placebo},
   language = {eng},
   issn = {1368-8375},
   journal = {Oral oncology},
   title = {c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside},
   url = {http://www.sciencedirect.com/science/article/pii/S136883751630063X},
   volume = {59},
   year = {2016}
}

TY  - JOUR
ID  - 1354105
AU  - Szturz, Petr - Raymond, E. - Faivre, S.
PY  - 2016
TI  - c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside
JF  - Oral oncology
VL  - 59
IS  - AUG 2016
SP  - "E12"-"E14"
EP  - "E12"-"E14"
PB  - ELSEVIER SCIENCE BV
SN  - 13688375
KW  - squamous-cell carcinoma
KW  - randomized phase-ii
KW  - tivantinib arq 197
KW  - lung-cancer
KW  - acquired-resistance
KW  - metastatic head
KW  - plus erlotinib
KW  - double-blind
KW  - patients pts
KW  - placebo
UR  - http://www.sciencedirect.com/science/article/pii/S136883751630063X
N2  - Mesenchymal–epithelial transition factor (c-MET), found on melanocytes, endothelial cells, and epithelial tissues, is a membrane spanning receptor tyrosine kinase for hepatocyte growth factor (HGF), produced by elements of mesenchymal origin. The receptor-ligand pair controls diverse biological activities including cell proliferation, motility, invasiveness, morphogenesis, apoptosis, and angiogenesis.
ER  -

SZTURZ, Petr, E. RAYMOND and S. FAIVRE. c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside. \textit{Oral oncology}. AMSTERDAM: ELSEVIER SCIENCE BV, 2016, vol.~59, AUG 2016, p.~''E12''-''E14'', 3 pp. ISSN~1368-8375. Available from: https://dx.doi.org/10.1016/j.oraloncology.2016.05.017.

Detailed Information on Publication Record